We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
SGLT2 inhibitors and autophagy in diabetes.
- Authors
Yaribeygi, Habib; Maleki, Mina; Atkin, Stephen L.; Jamialahmadi, Tannaz; Sahebkar, Amirhossein
- Abstract
Autophagy is a physiological event in mammalian cells to promote cell survival and efficiency in tissues, but it may turn to be a pathological process in disease conditions such as in diabetes. Chronic hyperglycemia induces aberrant autophagy and promotes cellular death as a main underlying cause of diabetes‐related complications. Therefore, autophagy‐modifying therapy may be of value to prevent the development of complications. Sodium‐glucose cotransporter 2 inhibitors (SGLT2is) are a class of newly introduced antidiabetic drugs that achieve normoglycemia through causing overt glycosuria. There is evidence that these drugs may have pleiotropic extra‐glycemic benefits, but their effect on the autophagy process is unclear; therefore, this review was undertaken to clarify the possible effects of SGLT2is on autophagy. Significance statement: In this review we evaluated the potential modification of autophagy by sodium‐glucose cotransporter 2 inhibitor (SGLT2i) drugs that are used to treat type 2 diabetes. Whilst autophagy is a critical and normal cellular protective process, in the presence of hyperglycemia the autophagic process may become dysfunctional and promote cell death contributing to the development of diabetes‐related complications. This suggests that SGLTi may have a role in autophagy‐modifying therapy.
- Subjects
SODIUM-glucose cotransporter 2 inhibitors; CANAGLIFLOZIN; AUTOPHAGY; SODIUM-glucose cotransporters; TYPE 2 diabetes; CELL survival
- Publication
Cell Biochemistry & Function, 2023, Vol 41, Issue 4, p392
- ISSN
0263-6484
- Publication type
Article
- DOI
10.1002/cbf.3792